Clinical trial
Interleukin-2 Plus Monoclonal Antibody Therapy in Treating Patients With Solid…
NCT00002994 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00002994 |
|---|---|
| Title | Interleukin-2 Plus Monoclonal Antibody Therapy in Treating Patients With Solid Tumors |
| Official title | A Pilot Study of Low-Dose Interleukin-2 Plus Recombinant Human Anti-HER2 Monoclonal Antibody in Solid Tumors |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Biological |
| Interventions | interleukin 2, rhuMAb |
| Enrollment | 355 |
| Start date | Jul 1, 1997 |
| Primary completion | Mar 1, 2000 |
| Completion | Apr 1, 2002 |
| First posted | Jul 19, 2004 |
| Last update posted | Jun 28, 2016 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: